Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
| Autor: | André, Thierry *, Falcone, Alfredo, Shparyk, Yaroslav, Moiseenko, Fedor, Polo-Marques, Eduardo, Csöszi, Tibor, Campos-Bragagnoli, Arinilda, Liposits, Gabor, Chmielowska, Ewa, Aubel, Paul, Martín, Lourdes, Fougeray, Ronan, Amellal, Nadia, Saunders, Mark P |
|---|---|
| Zdroj: | In The Lancet Gastroenterology & Hepatology February 2023 8(2):133-144 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|